News
Media
Conferences
Blog
Publications
Partners
Resources
Subscribe
CE

Opinion|Videos|July 16, 2024

Factors to Consider in Treatment Selection for MGD

Author(s)Jessilin Quint, OD, MBA, MS, FAAO, Selina R. McGee, OD, FAAO, Dipl ABO

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO, discuss the first-line treatment of MGD, highlighting factors that inform treatment selection.

Episodes in this series

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 1 Overview of MGD and Its Causes

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 2 Differentiating Aqueous vs Evaporative Dry Eye

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 3 Long-Term Consequences of Untreated MGD

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 4 Factors to Consider in Treatment Selection for MGD

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 5 Managing Evaporative Dry Eye with New FDA-Approved Therapy

Selina McGee, OD, FAAO, and Jessilin Quint, OD, MBA, FAAO

EP. 6 Differentiating Between the Semi-Fluorinated Alkane-Based Therapies for Dry Eye

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

EP. 7 Combining In-Office and At-Home Therapies

Jessilin Quint, OD, MBA, FAAO, and Selina McGee, OD, FAAO

EP. 8 Clinical Case Scenario: Management Strategies for MGD and Key Takeaways

Video content above is prompted by the following questions:

What is your first-line treatment for MGD? What factors do you consider when selecting treatment options for MGD for your patients?

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Related Content

Julie McLaughlin, OD, DipABO

Simplifying the treatment of ocular surface disease

ByJulie McLaughlin, OD, DipABO

July 20th 2026

Esen K. Akpek, MD

Classifying dry eye by root cause: A step toward precision medicine

ByLucia Gambuzza,Esen K. Akpek, MD

July 17th 2026

Eye drop Image credit: AdobeStock

NMPA in China approves Heng Yi cyclosporine drop

ByOptometry Times Staff Reports

July 10th 2026

Mila Ioussifova, OD, CNS, FAAO, FOWNS

What to consider when treating patients with dry eye and menopause

ByMila Ioussifova, OD, FAAO,Jordana Joy, Editor

July 10th 2026

Ping Moore, OD

Understanding meibomian gland dysfunction, neuropathic pain, and the evolving dry eye patient

ByYun Ping Moore, OD,Lucia Gambuzza

July 9th 2026

Latest CME

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Solange Peters, MD, PhD; Benjamin P. Levy, MD; Tony S.K. Mok, MD, BMSc, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO; Maurice Pérol, MD

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

PER Global Perspectives: Differentiating and Managing Toxicities with TROP2-Targeted ADCs in NSCLC Through Multidisciplinary Pathways

Solange Peters, MD, PhD; Stephanie McDonald, FNP-BC, AOCNP; Antonio Passaro, MD, PhD; Jacob Sands, MD

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

SriniVas Sadda, MD, FARVO; Nathan Steinle, MD

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

SriniVas R. Sadda, MD, FARVO; Hong-Uyen Hua, MD; Adrienne W. Scott, MD, FASRS

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Mark R. Barakat, MD, FASRS; David Eichenbaum, MD, FASRS

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Ramiro Maldonado, MD; Rebecca Nelson, MS, CGC; Robert A. Sisk, MD, FACS, FASRS

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

David Almeida, MD, PhD, MBA; Margaret A. Chang, MD, MS; Arshad M. Khanani, MD, MA, FASRS; Jessica Randolph, MD

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Dante Pieramici, MD, FASRS; Dean Eliott, MD; Robin A. Vora, MD; Charles C. Wykoff, MD, PhD, FASRS

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

Dilsher Dhoot, MD, FASRS; Jordana G. Fein, MD, MS; Deep Parikh, MD; Xiao-Yi (Ellie) Zhou, MD

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Judy E. Kim, MD, FARVO, FASRS; Anat Loewenstein, MD, MHA; Deepak Sambhara, MD, FASRS

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

In-Person + Virtual Event

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

September 13, 2026

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

SriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRS

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Stephen C. Pflugfelder, MD; Cecelia Koetting, OD, FAAO, DipABO

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Basil Williams, MD; Maura Di Nicola, MD

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

John Kitchens, MD; Michael W. Stewart, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - California

Dilsher S. Dhoot, MD, FASRS

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - NYC Metro

Deep Parikh, MD

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Bridging Regional Challenges in Retinal Disease Management: Applying Advanced Anti-VEGF Therapy in Community Practice - Florida

Carl J. Danzig, MD, FASRS

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

The Presbyopia-Correcting and Toric IOL Playbook: Game-Changing Surgical Strategies to Enhance Patient Outcomes

Uday Devgan, MD, FACS, FRCS

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

When Mites Meet Their Match: Empowering Patients With Targeted Treatment for 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis

Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

FDA approves Outlook Therapeutics' Lytenava for wet AMD

Frantz EyeCare reports high refractive accuracy with Light Adjustable Lens

i-Lumen Scientific enrolls first US patient in i-SIGHT2 pivotal trial of i-Lumen AMD System

Rethinking OCT biomarkers in DME: Baseline acuity and thickness outperform the rest

iVeena completes end-of-phase 1 FDA meeting for IVMED-85 in myopia